According to a new report published by KD Market Insights, titled, “Glioblastoma Multiforme Treatment Market Insights, Trends, Opportunity & Forecast, 2023–2032,”. The increasing prevalence of glioblastoma multiforme, advancements in research and development, and favorable regulatory scenarios. The presence of a robust pipeline and the rising incidence of brain tumors which are the major factors augmenting the growth of the global glioblastoma multiforme treatment market. The global glioblastoma multiforme treatment market is anticipated to grow at a robust CAGR of 8.9% from 2023 to 2032. The market's revenue surged to $2.5 billion in 2022, and it is expected to further accelerate, reaching a notable $5.8 billion by 2032.
The increasing prevalence of brain disorders, particularly glioblastoma multiforme, fuels the demand for effective treatment options. The rising incidence of this aggressive form of malignant tumor necessitates advanced and innovative therapies to improve patient outcomes are further expected to create ample growth opportunities for the global glioblastoma multiforme treatment market during the forecast period i.e., 2023-2032. Moreover, strong research and development (R&D) initiatives has propelled market expansion. Increasing aging population worldwide, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global glioblastoma multiforme treatment market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the robust government support for the healthcare sector, high awareness about rare disorders, easy access to quality medical facilities, and favorable reimbursement policies.
According to treatment, the radiation therapy segment accounted for the largest market share in the glioblastoma multiforme treatment market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global glioblastoma multiforme treatment market is segmented into treatment, drug class, end use and region. Based on treatment, the market is bifurcated into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, immunotherapy. Based on drug class, it is classified into temozolomide, bevacizumab, lomustine, carmustine wafers, others. Based on end use, it is classified into hospitals, clinics, ambulatory surgical centers.
The global glioblastoma multiforme treatment market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Glioblastoma multiforme treatment Market
Some of the major glioblastoma multiforme treatment companies profiled in the report include Amgen, Amneal Pharmaceuticals, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
About KD Market Research Insights
KD Market Research Company is a reputable and industry-leading market research firm that offers insightful insights, Analytics, and Research Reports for a variety of industries. With an emphasis on providing accurate and actionable market insights and data, our team of experienced research analysts conducts exhaustive research to assist businesses in making informed decisions. Whether you require market forecasts, competitive analysis, or the identification of trends, we offer comprehensive solutions tailored to your specific requirements. Stay ahead of the competition with the dependable market research services of KD Market Research Company.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
According to a new report published by KD Market Insights, titled, “Glioblastoma Multiforme Treatment Market Insights, Trends, Opportunity & Forecast, 2023–2032,”. The increasing prevalence of glioblastoma multiforme, advancements in research and development, and favorable regulatory scenarios. The presence of a robust pipeline and the rising incidence of brain tumors which are the major factors augmenting the growth of the global glioblastoma multiforme treatment market. The global glioblastoma multiforme treatment market is anticipated to grow at a robust CAGR of 8.9% from 2023 to 2032. The market's revenue surged to $2.5 billion in 2022, and it is expected to further accelerate, reaching a notable $5.8 billion by 2032.
The increasing prevalence of brain disorders, particularly glioblastoma multiforme, fuels the demand for effective treatment options. The rising incidence of this aggressive form of malignant tumor necessitates advanced and innovative therapies to improve patient outcomes are further expected to create ample growth opportunities for the global glioblastoma multiforme treatment market during the forecast period i.e., 2023-2032. Moreover, strong research and development (R&D) initiatives has propelled market expansion. Increasing aging population worldwide, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global glioblastoma multiforme treatment market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the robust government support for the healthcare sector, high awareness about rare disorders, easy access to quality medical facilities, and favorable reimbursement policies.
According to treatment, the radiation therapy segment accounted for the largest market share in the glioblastoma multiforme treatment market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global glioblastoma multiforme treatment market is segmented into treatment, drug class, end use and region. Based on treatment, the market is bifurcated into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, immunotherapy. Based on drug class, it is classified into temozolomide, bevacizumab, lomustine, carmustine wafers, others. Based on end use, it is classified into hospitals, clinics, ambulatory surgical centers.
The global glioblastoma multiforme treatment market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Glioblastoma multiforme treatment Market
Some of the major glioblastoma multiforme treatment companies profiled in the report include Amgen, Amneal Pharmaceuticals, Arbor Pharmaceuticals, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
About KD Market Research Insights
KD Market Research Company is a reputable and industry-leading market research firm that offers insightful insights, Analytics, and Research Reports for a variety of industries. With an emphasis on providing accurate and actionable market insights and data, our team of experienced research analysts conducts exhaustive research to assist businesses in making informed decisions. Whether you require market forecasts, competitive analysis, or the identification of trends, we offer comprehensive solutions tailored to your specific requirements. Stay ahead of the competition with the dependable market research services of KD Market Research Company.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com